Francisco Javier Javier Arrambide Garza

Dr. Francisco Javier Javier Arrambide Garza


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2023 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
JGJuventino Tadeo Guerrero-Zertuche
Juventino Tadeo Guerrero-Zertuche
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
AQAlejandro Quiroga-Garza
Alejandro Quiroga-Garza
AEAbraham Espinosa-Uribe
Abraham Espinosa-Uribe
RERodrigo Enrique Elizondo-Omaña
Rodrigo Enrique Elizondo-Omaña

5 December 2024 in The American Journal of Surgery
Verified
Journal Article
Closed access
LALuis Adrian Alvarez-Lozada
Luis Adrian Alvarez-Lozada
BFBernardo Alfonso Fernandez-Reyes
Bernardo Alfonso Fernandez-Reyes
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
MGMariana García-Leal
Mariana García-Leal
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
AQAlejandro Quiroga-Garza
Alejandro Quiroga-Garza

25 October 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
EMEmilio Moreno
Emilio Moreno
LALuis Adrian Alvarez-Lozada
Luis Adrian Alvarez-Lozada
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
AQAlejandro Quiroga-Garza
Alejandro Quiroga-Garza
RERodrigo Enrique Elizondo-Omaña
Rodrigo Enrique Elizondo-Omaña
We read with great interest and applaud the recently published review paper regarding ChatGPT and its implications in research and education

19 December 2025 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Closed access
PDF file
FVFelix Vílchez-Cavazos
Felix Vílchez-Cavazos
LRLuis Alejandro Rodriguez-Corpus
Luis Alejandro Rodriguez-Corpus
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
CACarlos Acosta-Olivo
Carlos Acosta-Olivo
MSMario Simental-Mendía
Mario Simental-Mendía

6 February 2024 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
JGJuventino Tadeo Guerrero-Zertuche
Juventino Tadeo Guerrero-Zertuche
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
AQAlejandro Quiroga-Garza
Alejandro Quiroga-Garza
AEAbraham Espinosa-Uribe
Abraham Espinosa-Uribe
RERodrigo Enrique Elizondo-Omaña
Rodrigo Enrique Elizondo-Omaña

1 March 2026 in Clinics in Shoulder and Elbow
Verified
Journal Article
Open access
PDF file
CACarlos Acosta-Olivo
Carlos Acosta-Olivo
GVGregorio Villarreal-Villarreal
Gregorio Villarreal-Villarreal
RSRicardo Salinas-Garza
Ricardo Salinas-Garza
VPVíctor Manuel Peña
Víctor Manuel Peña
FGFrancisco Javier Javier Arrambide Garza
Francisco Javier Javier Arrambide Garza
MSMario Simental-Mendía
Mario Simental-Mendía
Background: Tranexamic acid (TXA) is widely used to reduce bleeding and transfusion requirements during orthopedic procedures. The objective of this review was to evaluate the efficacy of TXA in the arthroscopic repair of rotator cuff tears.Methods: This systematic review and meta-analysis focused exclusively on randomized controlled trials, sourcing data from Medline, Embase, Web of Science, Scopus, and Cochrane Central up to January 2025. This review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis, and evaluated parameters such as visualization in the surgical field, pain, function, total operation time, mean arterial pressure, amount of fluid lost, hospital stay, tear size, and complications.Results: Initially, 298 records were identified. After a comprehensive screening process, 12 studies involving 967 patients were selected for inclusion. Most of the included studies used a saline solution as the control, and the most common route of TXA administration was intravenous, with a dose of 1,000 mg diluted in 100 mL of solution. In the parameters evaluated, no significant differences were found favoring the use of TXA. There was limited comparability of the results reported across the included studies.Conclusions: This study finds a lack of clear evidence to support a clinical benefit of TXA in arthroscopic rotator cuff repair. Consequently, the routine use of TXA for this procedure should be reconsidered. Given its established safety profile, TXA might still have a role in specific, limited clinical situations in which its benefits could outweigh the current lack of evidence for its widespread application.Level of evidence: I.